Fifth Amendment to Management Services Agreement between PAVmed Inc. and Lucid Diagnostics Inc.
PAVmed Inc. and Lucid Diagnostics Inc. have agreed to amend their existing Management Services Agreement. Effective October 15, 2021, the service fee paid under the agreement will increase from $290,000 to $390,000. All other terms of the original agreement remain unchanged. This amendment was signed by both parties on November 10, 2021.
Exhibit 10.4.6
FIFTH AMENDMENT TO MANAGEMENT SERVICES AGREEMENT
Reference is made to the Management Services Agreement (as amended from time to time, the “Agreement”; capitalized terms used but not defined herein have the meaning ascribed to them in the Agreement), dated as of May 12, 2018, by and between PAVmed Inc., a Delaware corporation (“PAVmed”) and Lucid Diagnostics Inc., a Delaware corporation (“Customer”).
WHEREAS, as set forth in Section 3(b) of the Agreement, the parties have considered in good faith an adjustment to the Service Fee and hereby wish to amend the Agreement to reflect such adjustment as set forth herein.
NOW, THEREFORE, in consideration of the foregoing and the mutual agreements hereinafter set forth, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereby agree as follows:
1. Amendment. The first sentence of Section 3(a) of the Agreement is hereby amended effective October 15, 2021 by replacing “$290,000” with “$390,000” having previously been amended on February 1, 2021 from “$190,000 to “$290,000”.
2. Terms of Agreement. Except as expressly set forth in this amendment, the terms of the Agreement remain unchanged and in full force and effect.
IN WITNESS WHEREOF, the parties have executed this agreement as of November 10, 2021.
AGREED AND ACCEPTED BY:
PAVmed Inc. | Lucid Diagnostics Inc. | |||
Name: | Lishan Aklog, MD | Name: | Lishan Aklog, MD | |
Title: | Chairman & CEO | Title: | Chairman & CEO |